AEZS - エテルナ・ゼンタリス （AEterna Zentaris Inc.） エテルナ・ゼンタリスAEZSのチャート
AEZSの企業情報
| symbol | AEZS |
|---|---|
| 会社名 | AEterna Zentaris Inc （エテルナ・ゼンタリス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 エテルナ・ゼンタリス(AEterna Zentaris Inc.)は腫瘍と内分泌療法を専門にする医薬品開発企業。同社の製品パイプラインは創薬から市販製品までの開発のすべての段階における化合物を含む。腫瘍における優先順位は多発性骨髄腫に対するペリホシンを投与したフェーズ３プログラムと転移性大腸癌を含む多発性癌に対するフェーズ２プログラム、並びに進行性子宮内膜癌と進行性卵巣癌に対するAEZS-108を投与したフェーズ２プログラム、また他の癌適応症における潜在的な発展を含む。内分泌では同社のプログラムは成人成長ホルモン分泌不全症(AGHD)の診断のための成長ホルモン(GH) 刺激試験とするAEZS-130(SolorelTM)を投与したフェーズ３相試験の再活性化である。 エテルナ・ゼンタリスはカナダのバイオ医薬品メ―カ―。腫瘍及び内分泌疾患の治療法の開発、商業化に従事。パイプラインは、薬品の発見から開発、製品の販売までが含まれる。製品候補には、小児充実性腫瘍、子宮内膜がん、卵巣がん、前立腺がん、がん悪液質などの新治療薬がある。本社はカナダ・ケベック州。 Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company's lead product, macimorelin, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macimorelin is currently marketed in the United States under the tradename Macrilen™through a license agreement with Novo Nordisk where Aeterna Zentaris receives royalties on sales. According to a commercialization and supply agreement, MegaPharm Ltd. will seek regulatory approval and then commercialize macimorelin in Israel and the Palestinian Authority. Additionally, upon receipt of pricing and reimbursement approvals, Aeterna expects that macimorelin will be marketed in Europe and the United Kingdom through a recently established license agreement with Consilient Health Ltd and Aeterna Zentaris will receive royalties on sales and other potential payments. |
| 本社所在地 | 1405 du Parc-Technologique Blvd. Quebec City Quebec G1P 4P5 CAN |
| 代表者氏名 | Carolyn Egbert キャロリン・エグベルト |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 843-900-3223 |
| 設立年月日 | 33117 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 56人 |
| url | www.aezsinc.com |
| nasdaq_url | https://www.nasdaq.com/symbol/aezs |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 5.17900 |
| 終値（lastsale） | 1.67 |
| 時価総額（marketcap） | 27456069.2 |
| 時価総額 | 時価総額（百万ドル） 28.28272 |
| 売上高 | 売上高（百万ドル） 25.24500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 8.33672 |
| 当期純利益 | 当期純利益（百万ドル） 1.70700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 AEterna Zentaris Inc. (USA) revenues increased from $504K to $24.8M. Net income totaled $11.8M vs. loss of $6.7M. Revenues reflect Licensing revenue increase from $220K to $24.7M. Net Income reflects Research and development costs net of r decrease of 70% to $1.8M (expense) Selling expenses decrease of 29% to $2.1M (expense). |
AEZSのテクニカル分析
AEZSのニュース
Q1 2023 EPS Estimates for Aeterna Zentaris Inc. Lowered by Analyst (NASDAQ:AEZS) 2023/03/31 06:22:41 The AM Reporter
Aeterna Zentaris Inc. (NASDAQ:AEZS – Get Rating) (TSE:AEZ) – HC Wainwright reduced their Q1 2023 earnings estimates for shares of Aeterna Zentaris in a research report issued to clients and investors on Tuesday, March 28th. HC Wainwright analyst B. Pachaiyappan now forecasts that the biopharmaceutical company will post earnings per share of ($1.07) for the […]
Aeterna Zentaris GAAP EPS of -$2.56, revenue of $2.5M 2023/03/23 12:39:54 Seeking Alpha
Aeterna Zentaris press release (AEZS): Q4 GAAP EPS of -$2.56.Revenue of $2.5M (+150.0% Y/Y).The Company had $50.6 million in cash and cash equivalents at December 31, 2022.
Aeterna Zentaris: Q4 Earnings Snapshot 2023/03/23 12:31:58 WTOP
TORONTO (AP) — TORONTO (AP) — Aeterna Zentaris Inc. (AEZS) on Thursday reported a loss of $12.5 million in its…
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results 2023/03/23 12:05:00 GlobeNewswire
– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025 – Executing strategy to streamline advancement of development programs, build upon growing body of data across pipeline, and progress towards go/no-go decision milestones – Ongoing efforts to accelerate recruitment for our DETECT trial and establish partnering rights to Macrilen ™ in the U.S. and Canada
Aeterna stock rises ~10% after Pharmanovia acquires rights to Ghryvelin in EU, UK 2023/03/16 12:39:43 Seeking Alpha
Aeterna Zentaris (AEZS) said Pharmanovia acquired a license to growth hormone therapy Ghryvelin from Aeterna''s existing licensee Consilient Health.Pharmanovia acquired exclusive rights…
Shocking stocks: Atossa Therapeutics, Inc. (NASDAQ:ATOS 2.38%), Aeterna Zentaris Inc. (NASDAQ:AEZS -0.21%) 2022/09/16 00:14:47 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Shocking stocks: Atossa Therapeutics, Inc. (NASDAQ:ATOS 2.38%), Aeterna Zentaris Inc. (NASDAQ:AEZS -0.21%) appeared first on Stocks Equity .
Deliciously stocks You Should follow: Verona Pharma plc (NASDAQ:VRNA 3.56%), Aeterna Zentaris Inc. (NASDAQ:AEZS -1.04%) 2022/09/15 00:11:52 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Deliciously stocks You Should follow: Verona Pharma plc (NASDAQ:VRNA 3.56%), Aeterna Zentaris Inc. (NASDAQ:AEZS -1.04%) appeared first on Stocks Equity .
Aeterna Zentaris to regain full rights to Macrilen oral test from Novo Nordisk 2022/08/29 14:12:12 Seeking Alpha
Aeterna Zentaris (AEZS) on Monday said it would regain the U.S. and Canadian rights for oral test Macrilen from Danish pharmaceutical company Novo Nordisk (NVO)
Aeterna Zentaris Inc. (NASDAQ: AEZS) Is A Blank Check For Growth 2022/08/06 13:30:00 Stocks Register
Aeterna Zentaris Inc. (NASDAQ:AEZS) shares, rose in value on Friday, 08/05/22, with the stock price up by 3.11% to the previous day’s close as strong demand from buyers drove the stock to $4.97. Actively observing the price movement in the last trading, the stock closed the session at $4.82, falling within a range of $4.6801 … Aeterna Zentaris Inc. (NASDAQ: AEZS) Is A Blank Check For Growth Read More »
Aeterna Zentaris GAAP EPS of -$0.87, revenue of $0.2M 2022/08/03 21:45:37 Seeking Alpha
Aeterna Zentaris press release (AEZS): Q2 GAAP EPS of -$0.87.Revenue of -$0.2M (vs
34 Stocks Moving in Wednesday''s Pre-Market Session 2022/05/11 11:05:01 Benzinga
Gainers Embark Technology, Inc. (NASDAQ: EMBK ) rose 36.4% to $1.95 in pre-market trading. Embark Technology posted a Q1 loss of $0.04 per share. Exicure, Inc. (NASDAQ: XCUR ) rose 36.4% to $0.1450 in pre-market trading after the company reported a $5 million raise in private placement transaction priced at market premium. Electra Battery Materials Corporation (NASDAQ: ELBM ) shares rose 34.5% to $4.99 in pre-market trading after the company issued an an Update on its Cobalt-Copper Mineral Project in Idaho. Desktop Metal, Inc. (NYSE: DM ) rose 23.3% to $1.64 in pre-market trading. Desktop Metal priced its $100 million convertible senior notes offering. New Concept Energy, Inc. (NYSE: GBR ) rose 19.7% to $2.25 in pre-market trading after declining 5% on Tuesday. Zai Lab Limited (NASDAQ: ZLAB ) rose 17.6% to $30.87 in pre-market trading following better-than-expected quarterly results. Evolve Transition Infrastructure LP (NYSE: SNMP ) shares rose 16.3% to $0.4650 in pre-market trading. Veru Inc. (NASDAQ: VERU ) rose 14.1% to $8.89 in pre-market trading.
Investors Focused Stock: Aeterna Zentaris Inc. (NASDAQ:AEZS), NuCana plc (NASDAQ:NCNA) 2022/03/24 01:41:26 Stock Equity
Aeterna Zentaris Inc. (NASDAQ:AEZS) with the stream of -1.07% also noticed, India NuCana plc (NASDAQ:NCNA) encountered a rapid change of -2.97% in the last hour of Wednesday’s trading session. Aeterna … The post Investors Focused Stock: Aeterna Zentaris Inc. (NASDAQ:AEZS), NuCana plc (NASDAQ:NCNA) appeared first on Stocks Equity .
Aeterna Zentaris Says Enrollment In Growth Hormone Deficiency Trial To Continue Into 2023 2022/03/21 16:22:12 Benzinga
Aeterna Zentaris Inc (NASDAQ: AEZS ) provided an update for its ongoing pivotal Phase 3 study AEZS-130-P02 (the DETECT-trial) of macimorelin to diagnose childhood-onset growth hormone deficiency (CGHD). The DETECT trial investigates the efficacy and safety of a single oral dose of 1.0 mg/kg macimorelin acetate as a growth hormone stimulation test … Full story available on Benzinga.com
Aeterna Zentaris pivotal growth hormone deficiency trial sees recruitment delays 2022/03/21 13:11:37 Seeking Alpha
Aeterna Zentaris (AEZS) said that enrollment of a phase 3 trial of macimorelin in childhood-onset growth hormone deficiency is delayed due to ongoing impacts from COVID-19 and Ukraine.
Beholding Stock: Cinedigm Corp. (NASDAQ:CIDM), Aeterna Zentaris Inc. (NASDAQ:AEZS) 2022/03/11 06:53:30 Stock Equity
Cinedigm Corp. (NASDAQ:CIDM) with the stream of -1.11% also noticed, India Aeterna Zentaris Inc. (NASDAQ:AEZS) encountered a rapid change of -0.97% in the last hour of Thursday’s trading session. Cinedigm … The post Beholding Stock: Cinedigm Corp. (NASDAQ:CIDM), Aeterna Zentaris Inc. (NASDAQ:AEZS) appeared first on Stocks Equity .